Results 1 to 10 of about 4,340 (195)

Improving the Thrombocytopenia Adverse Reaction of Belinostat Using Human Serum Albumin Nanoparticles [PDF]

International Journal of Nanomedicine
Jia-Yu Liu,1 Chia-Hung Yen,2,3 Ya-Fan Lin,4 Yin-Hsun Feng,5 Yi-Ping Fang1,6,7 1School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan; 2Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical ...
Liu JY, Yen CH, Lin YF, Feng YH, Fang YP
doaj   +4 more sources

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer [PDF]

Molecular Oncology
Identifying innovative therapeutic strategies is crucial to improve clinical management of ovarian cancer. Previously, we showed that ovarian cancer cell apoptosis can be triggered by inhibiting the anti‐apoptotic proteins Bcl‐xL and Mcl‐1 and/or by ...
Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu   +10 more
doaj   +3 more sources

Characterization of a Novel Family of Contilisant + Belinostat Multitarget Small Molecules in Glioblastoma [PDF]

Pharmaceuticals
Background: Glioblastoma is the most common and malignant primary brain tumor in adults, with current treatment presenting limited effectiveness. Therapeutic resistance stems largely from its marked molecular and cellular heterogeneity. Multitarget small
Aizpea Artetxe-Zurutuza, Nerea Iturrioz-Rodriguez, Joseba Elizazu, Raul Garcia-Garcia de Garayo, Irati de Goñi, Jhonatan Vergara, Mireia Toledano-Pinedo, Alicia Porro-Pérez, Mikel Azkargorta, Felix Elortza, Jose Luis Marco-Contelles, Nicolás Sampron, Ander Matheu   +12 more
doaj   +5 more sources

Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma

Tomography, 2022
Glioblastoma (GBM) is highly aggressive and has a poor prognosis. Belinostat is a histone deacetylase inhibitor with blood–brain barrier permeability, anti-GBM activity, and the potential to enhance chemoradiation.
Karen Xu, Karthik Ramesh, Vicki Huang, Saumya S. Gurbani, James Scott Cordova, Eduard Schreibmann, Brent D. Weinberg, Soma Sengupta, Alfredo D. Voloschin, Matthias Holdhoff, Peter B. Barker, Lawrence R. Kleinberg, Jeffrey J. Olson, Hui-Kuo G. Shu, Hyunsuk Shim   +14 more
doaj   +4 more sources

Tổng hợp, tiếp cận dược lý và đánh giá khả năng ức chế enzyme histone deacetylase 8 (HDAC8) in silico của một số dẫn xuất tương tự belinostat

Tạp chí Khoa học Đại học Cần Thơ, 2021
Thuốc điều trị ung thư hiện nay đang được sự quan tâm của các nhà nghiên cứu khoa học và enzyme histone deacetylase (HDAC) được đánh giá là một đích phân tử quan trọng nhất. Năm 2014, belinostat (Beleodaq) được FDA phê duyệt là một chất ức chế mạnh HDAC.
Nguyễn Cường Quốc, Nguyễn Thị Huỳnh Trang, Huỳnh Thanh Ngân, Đặng Thị Thu Thảo, Nguyễn Trọng Tuân, Bùi Thị Bửu Huê, Trần Quang Đệ   +6 more
doaj   +5 more sources

Hypophosphatemia as a Potential Class Effect of Histone Deacetylase Inhibitors: Evidence from Disproportionality Analysis and Mendelian Randomization Analysis of Drug Targets [PDF]

Pharmaceuticals
Background/Objective: Histone deacetylase inhibitors (HDACi) represent a novel class of antineoplastic agents, yet their comprehensive safety profile warrants further investigation.
Ruiqi Zhao, Bei Zhang, Mengyao Han, Minling Lv, Jialing Sun, Xiaozhou Zhou   +5 more
doaj   +2 more sources

New and Effective Inhibitor of Class I HDACs, Eimbinostat, Reduces the Growth of Hematologic Cancer Cells and Triggers Apoptosis [PDF]

Pharmaceutics
Background: Histone deacetylases (HDACs) are critical epigenetic modulators involved in regulating various molecular mechanisms essential for cell development and growth.
Pavel Spirin, Valeria Vedernikova, Tatsiana Volkava, Alexey Morozov, Alla Kleymenova, Anastasia Zemskaya, Lena Shyrokova, Yuri Porozov, Ksenia Glumakova, Timofey Lebedev, Maxim Kozlov, Vladimir Prassolov   +11 more
doaj   +2 more sources

Plasma protein levels and hepatocellular carcinoma: a Mendelian randomization study with drug screening implications [PDF]

Discover Oncology
Background Hepatocellular carcinoma (HCC) remains a significant cause of cancer-related mortality, highlighting the need for novel therapeutic strategies.
Longhui Xie, Dekun Song, Jianwei Lan, Pengpeng Liu, Shuang Qin, Yinkuan Ning, Quanyan Liu   +6 more
doaj   +2 more sources

Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors

Frontiers in Microbiology, 2021
The apicomplexan parasite, Theileria annulata, is the most prevalent hemoprotozoan in livestock, causing significant economic losses worldwide. It is essential to develop new and improved therapeutics, as current control measures are compromised by the ...
Madhumanti Barman, Sonam Kamble, Sonti Roy, Vasundhra Bhandari, Siva Singothu, Debabrata Dandasena, Akash Suresh, Paresh Sharma   +7 more
doaj   +1 more source

Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma

Experimental Hematology & Oncology, 2021
Background Belinostat is a histone deacetylase inhibitor approved for relapsed refractory peripheral T-cell lymphoma (PTCL). The primary objective of this study was to determine the maximum tolerated dose (MTD) of belinostat combined with CHOP (Bel-CHOP).
Patrick B. Johnston, Amanda F. Cashen, Petros G. Nikolinakos, Anne W. Beaven, Stefan Klaus Barta, Gajanan Bhat, Steven J. Hasal, Sven De Vos, Yasuhiro Oki, Changchun Deng, Francine M. Foss   +10 more
doaj   +1 more source